Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome

Journal of Endocrinological Investigation

Volumn 33, Issue 11, 2010, Pages 776-783

  Aversa, Antonio ^a   Bruzziches, R ^a   Francomano, D ^a   Spera, G ^a   Lenzi, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Erectile dysfunction; Long term controlled study; Obesity; Prostate volume; Side effects

Indexed keywords

PLACEBO; TESTOSTERONE; TESTOSTERONE UNDECANOATE; THYROID HORMONE;

ADULT; AGED; ARTICLE; BODY FAT; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FREE THYROXINE INDEX; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MEAL; METABOLIC PARAMETERS; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; THYROID HORMONE BLOOD LEVEL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE;

ADMINISTRATION, ORAL; BODY COMPOSITION; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; INSURANCE, PHARMACEUTICAL SERVICES; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PENILE ERECTION; TESTOSTERONE;

EID: 77957561521     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6903     Document Type: Article

References (44)

1. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009, 30: 10-22.
2. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009, 30: 23-32.
3. Fukui M, Kitagawa Y, Ose H, Hasegawa G, Yoshikawa T, Nakamura N. Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. Curr Diab Rev 2007, 3: 5-31.
4. Traish AM, Saad F, Feeley RJ, Guay AT. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009, 30: 477-94.
5. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006, 27: 57-64. (Pubitemid 41785933)
6. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002, 87: 589-8.
7. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86: 724-31. (Pubitemid 32207487)
8. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001, 22: 718-31. (Pubitemid 32781257)
9. Kshirsagar A, Seftel A, Ross L, Mohamed M, Niederberger C. Predicting hypogonadism in men based upon age, presence of erectile dysfunction, and depression. Int J Impot Res 2006, 18: 47-51. (Pubitemid 43050022)
10. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-8.
11. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006, 106: 581-8. (Pubitemid 43157621)
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Adult Treatment Panel III. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 2002, 106: 3143-421.
13. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366: 1059-62. (Pubitemid 41338752)
14. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007, 92: 3568-72. (Pubitemid 47435336)
15. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997, 82: 682-5. (Pubitemid 27068651)
16. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 2006, 27: 135-7.
17. Heinemann LAJ, Saad F, Zimmermann T, et al. The Aging Males' Symptoms (AMS) scale: Update and compilation of international versions. Health Qual Life Outcomes 2003, 1: 1-15.
18. Moore C, Huebler D, Zimmermann T, Heinemann LAJ, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004, 46: 80-7.
19. Heinemann LAJ, Saad F, Heinemann K, Thai DM. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004, 7: 211-8.
20. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999, 11: 319-26. (Pubitemid 30052683)
21. Prior BM, Cureton KJ, Modlesky CM, et al. In-vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J Appl Physiol 1997, 83: 623-30. (Pubitemid 27332782)
22. Bolanowski M, Nilsson BE. Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit 2001, 7: 1029-33. (Pubitemid 32928630)
23. Shinohara K. Transrectal ultrasonography in the evaluation of benign prostatic hyperplasia. In: Benign prostatic hyperplasia. Florida, USA: Churchill Livingston. 2000, 125-37.
24. Chenven ES, Glazier DB, Krisch EB et al. Evaluation of prostate volume by transrectal ultrasonography for use in a brachy therapy program. Urology 2001, 58: 752-5.
25. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003, 6: 1-7. (Pubitemid 36606394)
26. Haren M, Chapman I, Coates P, Morley J, Wittert G. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 2005, 34: 125-30. (Pubitemid 40331092)
27. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006, 154: 899-906. (Pubitemid 43997730)
28. Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28: 1636-42. (Pubitemid 41340902)
29. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007, 92: 4254-9. (Pubitemid 350074740)
30. Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009, 37: 74-90.
31. Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. J Steroid Biochem Mol Biol 2009, 114: 40-3.
32. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005, 63: 239-50. (Pubitemid 41233438)
33. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97: 3A-11A.
34. Aronne LJ. Classification of obesity and assessment of obesity related health risks. Obes Res 2002 10: 105S-15S.
35. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007, 156: 595-602. (Pubitemid 46796527)
36. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009, 32: 587-98.
37. Stanik S, Domfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 1981, 53: 828-32. (Pubitemid 13238668)
38. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004, 6: 208-15. (Pubitemid 38559701)
39. Strain G, Zumoff B, Rosner W, Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab 1994, 79: 1173-6. (Pubitemid 24342268)
40. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004, 6: 208-15. (Pubitemid 38559701)
41. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996, 81: 1821-6. (Pubitemid 26152470)
42. Corona G, Mannucci E, Petrone L, et al. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007, 4: 1038-45. (Pubitemid 47079637)
43. Corona G, Monami M, Boddi V, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 2010, 7: 1557-64..
44. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005, 63: 280-93. (Pubitemid 41233445)